Table 2 Cost-effectiveness of bevacizumab in the front-line treatment of ovarian cancer [13]

Cohn et al. 2011

PAC + CAR

2.5 million^a

10.3 months^b

Referent

Addition of BEV and maintenance BEV was not cost-effective

PAC + CAR + BEV

21.4 million^a

11.2 months^b

USD479,712 per PFLY gained

(PAC + CAR + BEV) + maintenance BEV

78.3 million^a

14.1 months^b

USD401,088 per PFLY gained

Barnett et al. 2013

PAC + CAR

PAC + CAR + BEV

PAC + CAR + BEV for high-risk patients

6220^c

20,751^c

56,351^c

2.80^d

2.89^d

2.88^d

Referent

USD168,610 per QALY

Dominated

Use of BEV with standard first-line taxane was not cost-effective in stage III/IV ovarian cancer. May be suitable in high-risk patients although ICER exceeded thresholds

Chan et al. 2014

PAC + CAR

535^e

10.5^b

Referent

For high-risk, advanced ovarian cancer patients, ICER was almost USD170,000 per life-year saved

PAC + CAR + BEV plus maintenance BEV

3760 (3225 for maintenance)^e

15.9^b

USD167,771 per LYG